Hyperfine (HYPR) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MaxCyte (MXCT) has outperformed Hyperfine (HYPR) over the past year, losing 40.0% versus a loss of 55.0%. Over five years, HYPR leads with a -90.5% price change compared with -90.8% for MXCT. MaxCyte is the larger company by market cap ($105.3 million vs $99.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPR | MXCT |
|---|---|---|
| Share price | $0.9401 | $1.02 |
| Market cap | $99.70M | $105.27M |
| 1-day change | +10.73% | -1.92% |
| YTD return | -3.97% | -34.19% |
| 1-year return | -55.02% | -40.00% |
| 5-year return | -90.54% | -90.75% |
| EPS (TTM) | $-0.37 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.22 | $1.87 |
| 52-week low | $0.754 | $0.643 |
| Distance from 52-week high | -57.65% | -45.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +115.93% | +302.94% |
| Average volume | 611.89K | 668.82K |
| Shares outstanding | 90.99M | 103.21M |
| Employees | 102 | 91 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MXCT has outperformed HYPR by 15.0 percentage points over the past year.
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Healthcare · Medical Devices · 102 employees
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Healthcare · Medical Devices · 91 employees
HYPR vs MXCT FAQ
Which is bigger, Hyperfine or MaxCyte?
MaxCyte (MXCT) is larger, with a market capitalization of $105.27M compared with $99.70M for Hyperfine (HYPR).
Which stock has performed better over the past year, HYPR or MXCT?
MXCT returned -40.00% over the past 12 months, compared with -55.02% for HYPR (price return, excluding dividends). Past performance does not predict future results.
Are Hyperfine and MaxCyte in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.